CN103130912B - 一步法制备共价交联和疏水改性海藻酸钠水凝胶 - Google Patents
一步法制备共价交联和疏水改性海藻酸钠水凝胶 Download PDFInfo
- Publication number
- CN103130912B CN103130912B CN201110393776.0A CN201110393776A CN103130912B CN 103130912 B CN103130912 B CN 103130912B CN 201110393776 A CN201110393776 A CN 201110393776A CN 103130912 B CN103130912 B CN 103130912B
- Authority
- CN
- China
- Prior art keywords
- sodium alginate
- gel
- lalgine
- linking
- decamethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical class CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 238000004132 cross linking Methods 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 10
- 239000000017 hydrogel Substances 0.000 title abstract description 19
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 40
- 239000000661 sodium alginate Substances 0.000 claims abstract description 40
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 37
- 230000032050 esterification Effects 0.000 claims abstract description 26
- 238000005886 esterification reaction Methods 0.000 claims abstract description 26
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 13
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 229920000554 ionomer Polymers 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000006227 byproduct Substances 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims description 2
- 238000005292 vacuum distillation Methods 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 abstract description 52
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract description 12
- 229960001680 ibuprofen Drugs 0.000 abstract description 12
- 239000011780 sodium chloride Substances 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000006555 catalytic reaction Methods 0.000 abstract 1
- 230000006837 decompression Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000008961 swelling Effects 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- INSRQEMEVAMETL-UHFFFAOYSA-N decane-1,1-diol Chemical compound CCCCCCCCCC(O)O INSRQEMEVAMETL-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012450 pharmaceutical intermediate Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110393776.0A CN103130912B (zh) | 2011-12-02 | 2011-12-02 | 一步法制备共价交联和疏水改性海藻酸钠水凝胶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110393776.0A CN103130912B (zh) | 2011-12-02 | 2011-12-02 | 一步法制备共价交联和疏水改性海藻酸钠水凝胶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103130912A CN103130912A (zh) | 2013-06-05 |
CN103130912B true CN103130912B (zh) | 2015-08-12 |
Family
ID=48491408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110393776.0A Expired - Fee Related CN103130912B (zh) | 2011-12-02 | 2011-12-02 | 一步法制备共价交联和疏水改性海藻酸钠水凝胶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103130912B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109134760B (zh) * | 2018-08-10 | 2020-01-14 | 江南大学 | 一种疏水改性海藻酸钠水凝胶的制备及应用 |
CN109646705B (zh) * | 2019-01-30 | 2022-06-14 | 深圳齐康医疗器械有限公司 | 复合海绵及其制备方法和负压引流敷料、装置与医疗设备 |
JP6809547B2 (ja) * | 2019-02-04 | 2021-01-06 | 日清紡ホールディングス株式会社 | 疎水性アルギン酸粒子群及びその製造方法 |
CN111481734B (zh) * | 2020-04-28 | 2022-04-15 | 北京诺康达医药科技股份有限公司 | 一种改性海藻酸钠自显影栓塞微球及其制备方法与应用 |
CN113024844B (zh) * | 2021-03-16 | 2021-09-24 | 盐城工学院 | 一种小分子交联剂增韧水凝胶及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7008476B2 (en) * | 2003-06-11 | 2006-03-07 | Az Electronic Materials Usa Corp. | Modified alginic acid of alginic acid derivatives and thermosetting anti-reflective compositions thereof |
ITMI20041373A1 (it) * | 2004-07-09 | 2004-10-09 | Lima Lto S P A | N-metil-ammidi di carbossimetilcellulosa acido alginico o carbossimetalamido |
CN101607999B (zh) * | 2009-07-23 | 2011-06-08 | 青岛正大海尔制药有限公司 | 一种藻酸双酯钠的制备方法 |
CN102219938A (zh) * | 2010-04-15 | 2011-10-19 | 江南大学 | 一种疏水改性海藻酸钠的制备方法 |
CN101942121B (zh) * | 2010-10-12 | 2011-12-14 | 山东大学威海分校 | 一种提高海藻酸钠粘度和稳定性的方法 |
-
2011
- 2011-12-02 CN CN201110393776.0A patent/CN103130912B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103130912A (zh) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Thermo-and pH-responsive HPC-g-AA/AA hydrogels for controlled drug delivery applications | |
CN103130912B (zh) | 一步法制备共价交联和疏水改性海藻酸钠水凝胶 | |
Martínez-Mejía et al. | Synthesis of new chitosan-glutaraldehyde scaffolds for tissue engineering using Schiff reactions | |
Ooi et al. | Cellulose nanocrystals extracted from rice husks as a reinforcing material in gelatin hydrogels for use in controlled drug delivery systems | |
Zhang et al. | Synthesis and characterization of partially biodegradable, temperature and pH sensitive Dex–MA/PNIPAAm hydrogels | |
Yin et al. | Glucose-responsive insulin delivery microhydrogels from methacrylated dextran/concanavalin A: preparation and in vitro release study | |
Don et al. | Preparation and characterization of chitosan-g-poly (vinyl alcohol)/poly (vinyl alcohol) blends used for the evaluation of blood-contacting compatibility | |
Wei et al. | Self-assembled, thermosensitive micelles of a star block copolymer based on PMMA and PNIPAAm for controlled drug delivery | |
Pacelli et al. | Dextran-polyethylene glycol cryogels as spongy scaffolds for drug delivery | |
Constantin et al. | Poly (NIPAAm-co-β-cyclodextrin) microgels with drug hosting and temperature-dependent delivery properties | |
Sharma et al. | Dynamic imine bond based chitosan smart hydrogel with magnified mechanical strength for controlled drug delivery | |
Fernández-Quiroz et al. | Effect of the molecular architecture on the thermosensitive properties of chitosan-g-poly (N-vinylcaprolactam) | |
Pan et al. | Dual-responsive IPN hydrogel based on sugarcane bagasse cellulose as drug carrier | |
Lin et al. | Thermosensitive in situ-forming dextran–pluronic hydrogels through Michael addition | |
CN102827293B (zh) | 一种炔基羟丙基纤维素及其温敏性水凝胶的制备方法与应用 | |
CN103554508B (zh) | 酸敏感两亲性星状嵌段共聚物、其制备方法及应用 | |
He et al. | Synthesis and physicochemical characterization of biodegradable and pH‐responsive hydrogels based on polyphosphoester for protein delivery | |
Michailova et al. | Nanoparticles formed from PNIPAM-g-PEO copolymers in the presence of indomethacin | |
Petrov et al. | Biocompatible cryogels of thermosensitive polyglycidol derivatives with ultra-rapid swelling properties | |
Cajot et al. | Novel functional degradable block copolymers for the building of reactive micelles | |
Wang et al. | Study on novel hydrogels based on thermosensitive PNIPAAm with pH sensitive PDMAEMA grafts | |
Hattori et al. | Synthesis of sulfonated amino-polysaccharides having anti-HIV and blood anticoagulant activities | |
Evans et al. | Optimized hydrophobically modified chitosan cryogels for strength and drug delivery systems | |
CN100389140C (zh) | 由聚肽-b-聚四氢呋喃-b-聚肽三嵌段共聚物制备纳米及微米级自组装体的方法 | |
Afgan et al. | Studies on non-gelatinous & thermo-responsive chitosan with the N-isopropylacrylamide by RAFT methodology for control release of levofloxacin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Tang Zhenghua Inventor before: Ni Caihua Inventor before: Wu Min Inventor before: Zhang Liping |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170927 Address after: 226500 Pujiang Road, Rugao City, Jiangsu, Nantong (Rugao port area) 8 Patentee after: RUGAO CITY LEHENG CHEMICAL Co.,Ltd. Address before: School of chemical engineering Jiangnan University No. 1800 214122 Jiangsu city of Wuxi Province Li Lake Avenue Patentee before: Jiangnan University |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150812 |